Here is another note from filing updating investigation.
They are refuting all claims and saying - "
The Company is continuing with the process of completing a New Drug Application for KIT-302, which is expected to be submitted to the FDA during the second quarter of 2017. In addition, the Company is continuing with all of its other ongoing activities, including its research and development activities in connection with KIT-302 and TyrNovo’s NT 219, further expanding its intellectual property portfolio and s..."